IL288755A - Compositions and methods for biological delivery vehicles - Google Patents

Compositions and methods for biological delivery vehicles

Info

Publication number
IL288755A
IL288755A IL288755A IL28875521A IL288755A IL 288755 A IL288755 A IL 288755A IL 288755 A IL288755 A IL 288755A IL 28875521 A IL28875521 A IL 28875521A IL 288755 A IL288755 A IL 288755A
Authority
IL
Israel
Prior art keywords
preparations
methods
biological substances
delivery carriers
carriers
Prior art date
Application number
IL288755A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dnalite Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnalite Therapeutics Inc filed Critical Dnalite Therapeutics Inc
Publication of IL288755A publication Critical patent/IL288755A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909Micelles formed by phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL288755A 2019-06-14 2021-12-07 Compositions and methods for biological delivery vehicles IL288755A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861852P 2019-06-14 2019-06-14
US201962948095P 2019-12-13 2019-12-13
PCT/US2020/037579 WO2020252375A1 (en) 2019-06-14 2020-06-12 Compositions and methods for biological delivery vehicles

Publications (1)

Publication Number Publication Date
IL288755A true IL288755A (en) 2022-02-01

Family

ID=73781318

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288755A IL288755A (en) 2019-06-14 2021-12-07 Compositions and methods for biological delivery vehicles

Country Status (8)

Country Link
US (1) US20220296516A1 (enExample)
EP (1) EP3982932A4 (enExample)
JP (1) JP7772597B2 (enExample)
CN (1) CN114286671A (enExample)
AU (1) AU2020290516B2 (enExample)
CA (1) CA3142949A1 (enExample)
IL (1) IL288755A (enExample)
WO (1) WO2020252375A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) * 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems
US20240050477A1 (en) * 2021-02-17 2024-02-15 National University Corporation Hokkaido University Lipid nanoparticle
US20240358651A1 (en) * 2021-04-01 2024-10-31 Snj Pharma Inc Oral nanoparticles for bioactive compound, and method of preparing same
KR102789632B1 (ko) * 2021-04-01 2025-04-01 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
KR20230141513A (ko) * 2022-03-22 2023-10-10 주식회사 바이오엔 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도
CN117247359A (zh) * 2022-06-09 2023-12-19 中国科学院广州生物医药与健康研究院 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用
WO2024006863A1 (en) * 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN118356505A (zh) * 2023-01-10 2024-07-19 复旦大学 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途
CN121443279A (zh) * 2023-06-28 2026-01-30 环球生命科学解决方案加拿大有限公司 用于细胞疗法的脂质纳米颗粒制剂和相关方法
WO2025021286A1 (en) * 2023-07-23 2025-01-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. A drug delivery system for increased endosomal escape
CN121752254A (zh) * 2023-08-11 2026-03-27 浙江海昶生物医药股份有限公司 一种具有靶向性的脂质组合物及其制备方法
US20250082776A1 (en) * 2023-08-31 2025-03-13 Massachusetts Institute Of Technology Polyanion coated lipid nanoparticles and methods of use thereof
PL248770B1 (pl) * 2023-11-23 2026-01-26 Politechnika Wroclawska Bilosomy o dodatnim ładunku i sposób ich wytwarzania
WO2025151073A1 (en) * 2024-01-10 2025-07-17 Agency For Science, Technology And Research Composition and nanoparticle suitable for use in the delivery of a therapeutic agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100817024B1 (ko) * 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
EP3494963A1 (en) * 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
EP2678350A1 (en) * 2011-02-22 2014-01-01 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
JP7164950B2 (ja) * 2014-10-31 2022-11-02 ユニバーシティー オブ ユタ リサーチ ファウンデーション 胆汁酸粒子の組成物及び方法
JP2018509387A (ja) * 2015-01-21 2018-04-05 フェーズアールエックス インコーポレイテッド 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
EP3675817A1 (en) * 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles

Also Published As

Publication number Publication date
JP7772597B2 (ja) 2025-11-18
WO2020252375A1 (en) 2020-12-17
JP2022538797A (ja) 2022-09-06
AU2020290516A1 (en) 2022-01-20
CN114286671A (zh) 2022-04-05
AU2020290516A2 (en) 2022-03-31
AU2020290516B2 (en) 2026-01-29
EP3982932A1 (en) 2022-04-20
EP3982932A4 (en) 2023-10-25
US20220296516A1 (en) 2022-09-22
CA3142949A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
IL288755A (en) Compositions and methods for biological delivery vehicles
IL281778A (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL282225A (en) Compositions and methods for immunotherapy
IL283840A (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
IL288909A (en) Methods of making bempedoic acid and compositions of the same
IL270814A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
IL268788A (en) Compositions and methods for enhanced gene expression
IL259246A (en) Compositions of therapeutic substances, methods and uses thereof
IL269150A (en) Compositions and methods for treating cancer
IL281082A (en) Compositions of cxcr4 inhibitors and methods of preparation and use
EP3743069C0 (en) BCL-2 PROTEIN-DEGRADING AGENTS FOR CANCER TREATMENT
IL281108A (en) Compositions and methods for enhancing donor oligonucleotide-based gene editing
IL268814A (en) Compositions and methods for treatment of cancer
EP3471735A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
IL268872A (en) Methods and compositions for treating cancers using antisense
IL281015A (en) Methods and compositions for the modification of plants
MA47119A (fr) Livraison de protéines au moyen de bactéries à virulence atténuée
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
IL269157A (en) Compositions and methods for treating cancer
IL280348A (en) Surface treatment compositions and methods
IL282251A (en) Compositions and methods for treatment of liver disease
IL285039A (en) Compositions and methods for stimulating natural killer cells
IL286811A (en) Compositions and methods for stabilizing protein-containing formulations
IL287423A (en) Antibodies and methods for treatment of influenza a infection
IL264593A (en) Pharmaceutical compositions comprising akt protein kinase inhibitors